At the Vienna site, Boehringer Ingelheim BioXcellence™ manufactures therapeutically active recombinant proteins and pDNA from microorganisms and yeast. Our highly-trained scientists in Vienna are dedicated to the biopharmaceutical business.
Boehringer Ingelheim BioXcellence™ operates several independent fermentation plants at its Vienna site - for E.coli and other bacteria as well as for yeast technologies, and with a flexible scale of up to 6,000 L. Both batch and fed-batch fermentations are performed. The modern facilities allow maximum flexibility and are designed for high-cell-density processes with high oxygen demands and which require high heat transfer rates. All plants are operated under a validated process control system.
The site in Vienna has been pioneering microbial fermentation process development for therapeutic proteins from E.coli since 1982.
Over the last decades, Boehringer Ingelheim's expertise and experience has broadened to include the development and manufacture of non-glycosylated proteins, antibody fragments and protein scaffolds, and plasmid DNA (pDNA) using E. coli and yeast expression technologies.
To supply the global market, biopharmaceuticals of microbial origin are produced in compliance with cGMP guidelines at our large-scale GMP manufacturing plant, which is equipped with bioreactors and offers a flexible scale of up to 6,000 L.
Fill & Finish
At the Vienna site, we offer Fill & Finish of lyophilized and liquid drug product in vials for clinical supply.
With the establishment of a new large-scale biopharmaceutical manufacturing facility, Vienna will become the fourth site for cell culture technology within Boehringer Ingelheim’s global manufacturing network. The investment of approximately half a billion Euros includes up to 150,000 L manufacturing capacities and will lead to the creation of more than 400 new jobs at Vienna. The innovative manufacturing plant will go into operation by 2021. The construction works started as planned in January 2017. The groundbreaking will take place at the beginning of April.
More information please visit following websites: